Pharma Stocks
-
Should Amylyx Pharmaceuticals’ Sharply Reduced Net Losses Prompt a Rethink by AMLX Investors?
Amylyx Pharmaceuticals announced third quarter 2025 results, reporting a net loss of US$34.39 million and a loss per share of…
Read More » -
Pharma stock jumps 4% after securing approval for cancer drugs across Europe & emerging markets
Synopsis: Sakar Healthcare jumped sharply after securing 9 new approvals for its oncology drugs across Europe and emerging markets, taking…
Read More » -
How Investors Are Reacting To Ionis Pharmaceuticals (IONS) Raising Revenue Guidance and Narrowing Losses
Ionis Pharmaceuticals reported third-quarter 2025 results, with revenue rising to US$156.72 million and net loss narrowing to US$128.61 million compared…
Read More » -
Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus
As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the…
Read More » -
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system…
Read More » -
Collegium Pharmaceutical (COLL): Examining the Stock’s Valuation After Recent Gains
Collegium Pharmaceutical (COLL) has shown steady gains over the past month, with the stock advancing 3% and building on its…
Read More » -
Tatva Chintan Pharma Chem Limited Just Beat EPS By 6.0%: Here’s What Analysts Think Will Happen Next
Shareholders of Tatva Chintan Pharma Chem Limited (NSE:TATVA) will be pleased this week, given that the stock price is up…
Read More » -
Takeda (TSE:4502) Valuation in Focus After Lowered FY2026 Guidance and VYVANSE Generic Impact
Takeda Pharmaceutical (TSE:4502) updated its outlook for the fiscal year ending March 2026, lowering guidance after reporting declines in both…
Read More » -
Pharma sector struggles, top firms hold ground
3 companies reported profit growth, 6 saw declines in FY25 02 November, 2025, 10:10 pm Last modified: 03 November, 2025,…
Read More » -
Strong Q3 Results Drive 11% Revenue Growth
TLDR Vertex’s Q3 2025 revenue jumps 11% driven by CF therapies and new drugs. Vertex’s cystic fibrosis treatments boost Q3…
Read More »